Online inquiry

IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9479MR)

This product GTTS-WQ9479MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5AR1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001736.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 728
UniProt ID P21730
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9479MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2087MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ4571MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ13312MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ15504MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ13456MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ4650MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ2329MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ9500MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J2898A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW